Kairos Pharma Ltd.

09/09/2025

September is Month, a moment raise awareness of ongoing , encourage regular screenings, and provide support to those affected by this disease.

The science team at have discovered a central mechanism responsible for the development of cancer drug resistance. As patients are treated with Xtandi, Zytiga, or Erleada (or other anti-androgen drugs) for , the cancer starts making a protein called CD105 on the cell surface, making it resistant to those drugs.

’s drug, , is an antibody that reverses the effect of CD105 to render the cancer responsive to those drugs again. It is currently in a Phase 2 in prostate cancer.

Learn more about our team’s efforts here: https://bit.ly/44X6gz7

ZERO Prostate Cancer Prostate Cancer Foundation

09/08/2025

is proud to announce that our Chief Scientific Officer, Neil Bhowmick, Ph.D., has been endowed with the Mark Goodson Chair in Oncology Research at Cedars-Sinai. The chair was formerly held by Phillip Koeffler, M.D.

Congratulations to Neil and all new chairs at !

Read more here: ceda.rs/4peFHi9

Cedars-Sinai has announced appointments of five endowed chairs to advance research in cancer, pulmonary and critical care medicine, and otology and neurotology.

09/04/2025

’s CEO & Chairman, John Yu, M.D., spoke with Phalguni Deswal of Drug Device and World on how is rethinking cancer drug resistance and advancing new .

Read the full Q&A article here: https://bit.ly/3I0rsNc

Kairos Pharma's CEO Dr. John Yu shares how his company is rethinking cancer drug resistance and advancing new immunotherapies.

09/03/2025

announces participation and presentation of initial Phase 1 data of ENV105 in non small cell by Principal Investigator, Dr. Karen Reckamp. Her presentation will be at the , taking place September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain.

Read more: bit.ly/4nj5WCt

09/02/2025

announces that John Yu, M.D., CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.

Learn more: bit.ly/3Vhh4nr

08/28/2025

’s CEO and Chairman, John Yu, M.D., joined Sully Speaks of once again to discuss ’s scientific approach, ongoing , and notable upcoming milestones. Check out the video below:

08/21/2025

Featuring 's Chief Scientific Officer, Neil Bhowmick, Ph.D., who brings over 20 years of broad experience filing and prosecuting patents in therapeutics and devices. He is also the President of Enviro Therapeutics, Inc., a fully owned subsidiary of Kairos Pharma Ltd. (NYSE: KAPA).

Along with his work leading the team, Dr. Bhowmick currently serves as an endowed chair of oncology research and Professor in the Department of Medicine at Cedars-Sinai Medical Center. Dr. Bhowmick Holds 6 patents for biomarker detection platforms and stromal targeted therapeutics (inclusive of
and ). His work has been funded by the NCI/NIH for over 20 years and his publications have been cited over 17,800 times.

Dr. Bhowmick is credited for defining the role of in cancer initiation as an alternative mechanism of the familiar cell-intrinsic two-hit hypothesis, where a mutation in the epithelia is complemented by one epigenetic alteration in fibroblasts. He has gone on to discover the role of fibroblasts in resistance and used this finding to extend the time of cancer remission in multiple cancer types through preclinical and clinical examples.

Learn more about our leadership team: https://lnkd.in/gGsvBUfJ

08/19/2025

’s CEO and Chairman, John Yu, M.D., recently spoke with Vatsala Gaur of about lead drug candidate ’s potential for and what partnerships could do for the growth of the company.

Read the full Q&A article here: https://invezz.com/news/2025/08/15/interview-kairos-pharma-ceo-john-yu-on-env105s-potential-partnerships-for-growth/

J

08/12/2025

’s Chief Executive Officer and Chairman, John Yu, M.D., recently spoke with Rachel Lee of CEO.CA about ’s latest safety data, which demonstrated zero grade 3 or 4 toxicities (compared to over 50% with standard treatments) from the company’s . The discussion also previews what to expect from September efficacy data, and upcoming expansion into and other tumor types.

Check out the full video interview below and learn more on our website: kairospharma.com

08/07/2025

’s ENV-105 was recently featured in an article in CURE Today that covered the top five highlights for patients in July. Check out the feature and a quote from ’s CEO and Chairman, John Yu, M.D., in the link below.

Read the article here: https://bit.ly/4lkFqHn

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.

08/06/2025

is committed to patients, caregivers, and the science of extending lives. Our focus is on developing to overcome cancer drug resistance and reverse cancer-induced immune suppression to help ensure a patients journey to recovery can continue without interruption.

Learn more on our website: kairospharma.com

08/05/2025

’s Chief Executive Officer and Chairman, John Yu, M.D., truly exemplifies what it means to be a jack of all trades. While he leads the team, Dr. Yu is also currently Professor of and Director Surgical Neuro-Oncology at Cedars-Sinai Medical Center.

In addition, Dr. Yu has developed 8 new investigational drugs with the U.S. Food and Drug Administration, has led numerous , and holds numerous patents for and from his funded laboratory.

Learn more about Dr. Yu and our incredible leadership team on our website: https://bit.ly/4lfeJ70